Stroke kills millions, but Osaka researchers have unveiled GAI-17, a drug that halts toxic GAPDH clumping, slashes brain ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Apigenin is a chemical compound naturally found in plants such as parsley, chamomile, and celery. There’s been some interest ...

A medical breakthrough could soon change how we diagnose one of the most devastating brain diseases of our time. On Bloom, I ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...

A university is leading research into how daffodils can help improve dementia treatment. The Royal Agricultural University ...

The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.